Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Observational Study on the Predictive Value of Cardiac Damage Markers High-sensitivity Cardiac Troponin I (Hs-cTnI), N-terminal Pro-B-natriuretic Peptide (NT-proBNP) and Soluble Suppression of Tumorigenesis-2 (sST2) for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV).

NCT06902857 is registered in ClinicalTrials.gov with Istituto Nazionale di Ricovero e Cura per Anziani as lead sponsor.

NCT NCT06902857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06902857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Observational Study on the Predictive Value of Cardiac Damage Markers High-sensitivity Cardiac Troponin I (Hs-cTnI), N-terminal Pro-B-natriuretic Peptide (NT-proBNP) and Soluble Suppression of Tumorigenesis-2 (sST2) for Mortality and the Development of Cardiovascular Events in Patients With Type 2 Diabetes (Diabetes-CV).
Lead sponsor
Istituto Nazionale di Ricovero e Cura per Anziani
Phase
Observational
Overall status
Active, not recruiting
Start date
April 18, 2024
Completion date
December 31, 2028
Enrollment
964 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular complication, type 2 diabetes